Pharma Times

MAY 20, 2021

Initial results trialling seven vaccines will inform plans for Autumn booster programme

Vaccines 123

Vaccines 123

Express Pharma

JULY 2, 2024

Techinvention Lifecare has been appointed as a consultant by Botswana Vaccine Institute (BVI) to monitor setting up of the new cGMP compliant, vaccine manufacturing unit in its existing facility at Gaborone, Botswana.

Vaccines 111

Vaccines 111

pharmaphorum

NOVEMBER 19, 2021

The race to find and bring vaccines to market to fight Covid was impressive. It’s been almost a year since the first Covid vaccine was authorised for use. Meanwhile, China and Russia have rolled out state-owned vaccines. Pfizer/BioNTech’s vaccine dominates the market. billion in vaccine sales this year.

Vaccines 137

Vaccines Communication 137

ALiEM - Pharm Pearls

JANUARY 12, 2024

A 42-year old Bengali man with a history of hyperlipidemia presented to the Emergency Department with facial swelling, diffuse rash, renal insufficiency and proteinuria after receiving his COVID-19 vaccine (Moderna) booster dose. Erythema multiforme has been reported as a cutaneous reaction after the COVID-19 mRNA vaccine.

Vaccines 130

Vaccines 130

Pharmaceutical Technology

DECEMBER 11, 2022

The US Food and Drug Administration (FDA) has granted Fast Track designation for Pfizer and BioNTech’s messenger ribonucleic acid (mRNA)-based combination vaccine candidate against Covid-19 and influenza. The vaccine is intended to prevent two respiratory ailments through a single injection. 5 Omicron sublineages spike proteins.

Vaccines 115

Vaccines Communication 115

Pharmaceutical Technology

APRIL 19, 2023

The US Food and Drug Administration (FDA) has made changes to the emergency use authorisations (EUAs) of the Pfizer -BioNTech and Moderna bivalent mRNA Covid-19 vaccines. The latest amendment aims to simplify the vaccination schedule for most people. The changes mean that the current bivalent vaccines for the original and Omicron BA.4/BA.5

Vaccines 133

Vaccines 133

pharmaphorum

MARCH 2, 2021

Zebra Technologies healthcare lead Chris Sullivan discusses the COVID-19 vaccine rollout and how technology can streamline the process to combat new variants. . While the rollout of the COVID-19 vaccine has signified the first signs of light at the end of the tunnel, the reality is that this public health crisis is still far from over.

Vaccines 119

Vaccines Adverse Reactions Documentation Labelling 119

pharmaphorum

DECEMBER 10, 2020

The European Medicines Agency (EMA) says it suffered a cyberattack, with documents relating to a Pfizer and BioNTech’s COVID-19 vaccine accessed. Shortly after however BioNTech confirmed that documents submitted as part of its marketing application for coronavirus vaccine BNT-162b had been accessed by the hackers.

Vaccines 111

Vaccines Documentation 111

pharmaphorum

JANUARY 31, 2022

It is becoming increasingly important for people all over the world to understand the importance of vaccines and to have access to the vaccines they need – especially with digital innovation driving new vaccine development. Pfizer’s Josh Raysman, Saad Saeed, and Shanaya Deboo discuss vaccine awareness, access, and innovation.

Vaccines 97

Vaccines Pharmaceutical Companies Pharmaceutical Companies Drug Development 97

pharmaphorum

DECEMBER 17, 2020

Tik Tok is unlikely to spring to mind as a source of reliable information about complex issues, but scientists are using it to fly the flag for COVID-19 vaccines and other health topics. When we talk about vaccines as health professionals, people who are vehemently anti-vaccine can take it out of context for their agenda.

Vaccines 97

Vaccines Communication Immunization Immunity 97

Pharmaceutical Business Review

FEBRUARY 27, 2024

The investment, led by MSD Global Health Innovation Fund and IQ Capital, with contributions from Hoxton Ventures, Creator Fund, Beast Ventures, and Maki.vc, will expedite the progress of Baseimmune’s technology and vaccine candidates.

Vaccines 105

Vaccines Immunity Immunization 105

Pharmaceutical Technology

JULY 6, 2023

The ICMRA says evidence from more than 13 billion global vaccine doses shows good safety amid “dangerous” false information.

Vaccines 98

Vaccines 98

European Pharmaceutical Review

AUGUST 22, 2022

THE GLOBAL outbreak of the COVID-19 pandemic triggered an urgent need to protect people’s lives and livelihoods and the healthcare community recognised quite early that vaccines were the best solution to this crisis. Novel biotechnology platforms for vaccine development.

Vaccines 98

Vaccines Immunity Immunization 98

Pharmaceutical Technology

FEBRUARY 23, 2023

GenScript ProBio has announced a strategic collaboration with RVAC Medicines to manufacture GMP-grade plasmid DNA (pDNA) for the latter’s RVM-V001, an mRNA Covid-19 vaccine candidate. The post GenScript ProBio and RVAC partner for Covid-19 vaccine pDNA appeared first on Pharmaceutical Technology.

Vaccines 115

Vaccines Communication 115

pharmaphorum

DECEMBER 17, 2020

Trials of a fifth COVID-19 vaccine have begun in the UK, as IT issues threaten to delay the roll-out of the shot from Pfizer/BioNTech. France’s Valneva begun the phase 1/2 clinical study of the inactivated vaccine candidate VLA2001 in sites across the UK, supported by the National Institute for Health Research (NIHR).

Vaccines 105

Vaccines Immunization Immunity Hospitals 105

pharmaphorum

DECEMBER 9, 2020

Reviewers from the FDA have given their blessing to the Pfizer/BioNTech COVID-19 vaccine ahead of a key meeting tomorrow – but the regulator noted that there are still uncertainties about whether the shot can stop the disease from spreading. The post FDA reviewers back Pfizer/BioNTech COVID-19 vaccine ahead of panel appeared first on.

Vaccines 111

Vaccines Adverse Reactions Documentation Immunization 111

European Pharmaceutical Review

AUGUST 3, 2022

Commission has established the mRNAVAC Working Party to begin working on quality standards to support the emerging field of messenger RNA (mRNA) vaccines. The newly created Working Party’s first task will be to develop a consolidated strategy for future standards addressing these vaccines and their components.

Vaccines 105

Vaccines 105

pharmaphorum

OCTOBER 2, 2020

European regulators have started a first ‘rolling review’ of a COVID-19 vaccine, which is being developed by AstraZeneca in collaboration with the University of Oxford. But this does not mean that the CHMP is ready to make a conclusion on the safety and efficacy of the vaccine.

Vaccines 105

Vaccines Immunization Immunity 105

pharmaphorum

MARCH 18, 2021

An EMA advisory committee’s review of AstraZeneca’s COVID-19 has concluded that there is no increase in the overall risk of blood clots with this vaccine. And because the vaccine is effective in preventing COVID-19 disease – which in itself is a cause of blood clots – it “likely reduces the risk of thrombotic events overall.”.

Vaccines 105

Vaccines Immunization Immunity 105

Pharmaceutical Technology

MARCH 20, 2023

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The mRNA vaccine candidates will help reduce the chances of autoimmune responses that might lead to allergic conditions or serious autoimmune diseases.

Vaccines 98

Vaccines Immunity Immunization Communication 98

Express Pharma

AUGUST 8, 2023

The Coalition for Epidemic Preparedness Innovations (CEPI) and Gennova Biopharmaceuticals announced a new funding agreement to advance the development of their self-amplifying mRNA (saRNA) platform to develop vaccine candidates against unknown pathogenic threats, also referred to as Disease X. CEPI will provide up to $3.6

Vaccines 98

Vaccines Immunization Immunity 98

Pharmaceutical Technology

MAY 2, 2023

4/5 Covid-19 messenger RNA (mRNA) vaccines. The expanded EUAs state that these current bivalent vaccines are now to be used for all primary and booster doses administered to individuals ages six months of age and older. 1 vaccines by both companies were revoked by the FDA in August 2022, after the BA.5

Vaccines 21

Vaccines Immunization Immunity 21

pharmaphorum

JUNE 30, 2021

Just a few months after starting clinical trials of its nasal spray vaccine for COVID-19, US biotech Altimmune is abandoning the project, saying that it generated weaker than expected immune responses in a phase 1 trial. . The post Altimmune ditches nasal COVID vaccine on weak trial data appeared first on.

Vaccines 98

Vaccines Immunization Immunity 98

PhRMA

AUGUST 16, 2022

Since the start of the pandemic, America’s biopharmaceutical companies have worked around the clock to research, develop and manufacture treatments and vaccines to fight COVID-19. We’ve made unprecedented progress in a short time thanks to decades of experience having produced over 14 billion vaccines globally to date.

Vaccines 103

Vaccines 103

The Pharmacist

NOVEMBER 1, 2023

Ensuring good access and information around vaccinations is ‘key’ to tackling health inequalities, director of market access and policy affairs at Moderna told delegates at a Westminster Health Forum this week.

Vaccines 84

Vaccines Pharmaceutical Companies Pharmaceutical Companies 84

Express Pharma

MAY 11, 2023

TechInvention Lifecare India, has partnered with Eubiologics Co, South Korea, to launch Euvichol-Plus, a oral cholera vaccine (OCV), in a low-density polyethylene (LDPE) unidose pack in India. The post TechInvention launches Euvichol-Plus, oral cholera vaccine in India appeared first on Express Pharma.

Vaccines 98

Vaccines Labelling 98

pharmaphorum

JUNE 2, 2021

In the latest edition of What HCPs Think , CREATION.co’s Laura Marsh looks at what healthcare professionals are saying about blood clots linked to COVID-19 vaccines. This sudden increase is due to reports of rare blood clots in recipients of the COVID-19 vaccines developed by AstraZeneca and more recently Johnson & Johnson.

Vaccines 105

Vaccines Hospitals 105

pharmaphorum

JANUARY 7, 2021

Shortly after launching large-scale trials of its COVID-19 vaccine candidate, CureVac has the partner it will need to roll the shot out at scale if it works as hoped. The post Bayer joins the COVID-19 vaccine push, backing CureVac shot appeared first on.

Vaccines 105

Vaccines 105

pharmaphorum

MARCH 23, 2021

AstraZeneca has been rebuked by a US health authority after a trial monitoring board said data published from a large study of its COVID-19 vaccine may be out of date and may not give a representative view of its efficacy. AstraZeneca is preparing to file this and other trial data with the FDA asking for an emergency approval of the vaccine.

Vaccines 98

Vaccines 98

pharmaphorum

SEPTEMBER 24, 2020

The UK could be the first country to carry out a COVID-19 “challenge trial” where healthy volunteers are deliberately infected with coronavirus to test vaccines, according to press reports. That vaccine is top of the World Health Organization’s list of vaccines in clinical development, which shows there are 38 potential shots in human trials.

Vaccines 98

Vaccines Immunization Immunity Hospitals 98

Community Pharmacy

OCTOBER 27, 2023

While COVID-19 might not be as pressing of a problem as it was during the peak of the pandemic, the virus and its many variants still pose significant health risks that require updated vaccine protection to combat. rise, which previous year’s vaccines were not designed to protect against.

Vaccines 105

Vaccines Community Pharmacies Hospitals Immunization 105

European Pharmaceutical Review

JANUARY 18, 2023

mRNA-1345 demonstrated vaccine efficacy (VE) of 83.7 percent in Moderna’s mRNA vaccine Phase III trial targeting respiratory syncytial virus (RSV) in older adults. ” Moderna’s mRNA vaccine – mRNA-1345. mRNA-1345 is an investigational RSV vaccine. Moderna launches two new mRNA vaccine programmes.

Vaccines 105

Vaccines Adverse Reactions 105

European Pharmaceutical Review

NOVEMBER 18, 2022

The World Health Organization (WHO)’s Global Vaccine Market Report 2022 , the first report to examine the impact of COVID-19 on the global vaccine market, shows that inequitable distribution is not unique to COVID-19 vaccines, with poorer countries consistently fighting to access vaccines in demand by wealthier countries.

Vaccines 98

Vaccines Immunization Immunity Documentation 98

pharmaphorum

OCTOBER 1, 2020

The EU regulator is poised to start a review of AstraZeneca and Oxford University’s COVID-19 vaccine, but the FDA is widening its investigation into the shot’s safety, according to reports citing people close to the project. The post EMA review of AZ’s COVID-19 vaccine imminent; report appeared first on.

Vaccines 93

Vaccines 93

Express Pharma

AUGUST 25, 2023

The survey shows that although 71 per cent of adults aged ≥50 years are aware of adult vaccination, only 16 per cent have taken any adult vaccines. A majority of doctors surveyed (90 per cent) state that a lack of formal guidelines results in a lack of interest and adoption of vaccination by patients.

Vaccines 98

Vaccines Diabetes 98

pharmaphorum

FEBRUARY 22, 2021

Sanofi and GlaxoSmithKline are restarting clinical development of their COVID-19 vaccine, which was delayed after hitting a snag late last year. In December interim phase 1/2 trial results showed the vaccine produced a lower immune response in older adults.

Vaccines 89

Vaccines Immunization Immunity Dosage 89

pharmaphorum

NOVEMBER 20, 2022

One standout success we have all benefitted from is vaccine development, with notable vaccines from Pfizer/BioNTech, AstraZeneca, and Moderna. New hurdles from COVID-19 vaccine development. Trials testing SARS-CoV-2 vaccines saw high enrollment, which reduced the time between each clinical trial phase.

Vaccines 98

Vaccines Immunization Immunity 98